menu
    • menu
    [{"orgOrder":0,"company":"Ossium Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Ossium Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ossium Health \/ Not Applicable"},{"orgOrder":0,"company":"Ossium Health","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"OSSM-007","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ossium Health \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ossium Health \/ California Institute of Regenerative Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Ossium Health

    Menu

    Ossium Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ossium Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ossium Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OSSM-007

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : California Institute of Regenerative Medicine

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Ossium Health Awarded $3.46M in Funding From The California Institute of Regenerative Medicine (CIRM) to Advan...

                            Details : The funding will advance the development of OSSM-007, an interferon-gamma primed mesenchymal stem cell product, for the treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD), with plans to initiate clinical study activities by the end of...

                            Brand Name : OSSM-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 28, 2023

                            Lead Product(s) : OSSM-007

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : California Institute of Regenerative Medicine

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ossium Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ossium Health

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal Stem Cell

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ossium Health Announces FDA Clearance of its Investigational New Drug Application for Treatment of Perianal Fi...

                            Details : OSSM-001, a mesenchymal stem cell (MSC) product is the second Ossium cell therapy product to enter the clinic, for the treatment of refractory perianal fistulas in patients with Crohn’s disease.

                            Brand Name : OSSM-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 16, 2022

                            Lead Product(s) : Mesenchymal Stem Cell

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth